Prosecution Insights
Last updated: April 19, 2026

Examiner: JAUHARI, SACHI

Tech Center 1600 • Art Units: 1654 1658

This examiner grants 0% of resolved cases

Performance Statistics

%
Allow Rate
-60.0% vs TC avg
8
Total Applications
+0.0%
Interview Lift
1175
Avg Prosecution Days
Based on 1 resolved cases, 2023–2026

Rejection Statute Breakdown

11.1%
§101 Eligibility
14.8%
§102 Novelty
48.2%
§103 Obviousness
25.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18389544 METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE Non-Final OA Jiu-Yao Wang
18490806 TOPICAL COMPOSITION FOR REGULATION OF INFLAMMATION AND SKIN REGENERATION Non-Final OA Glycopep Therapeutics, S.A.S. de C.V.
18464817 Dental Care Products Comprising Stannous Flouride Non-Final OA Credentis AG
18462852 SMALL-MOLECULE PEPTIDE AND USE THEREOF AGAINST METABOLIC-ASSOCIATED FATTY LIVER DISEASE AND FOR REDUCING BODY WEIGHT Non-Final OA Tunghai University
18237368 DESIGN AND CHARACTERIZATION OF INHIBITORY PEPTIDES (IPEPS) DERIVED FROM OF MIEN 1 PROTEIN SEQUENCE Non-Final OA The University of North Texas Health Sciences Cente
18043230 INTERLEUKIN-1 RECEPTOR MODULATORS AND USES THEREOF Non-Final OA VALORISATION-RECHERCHE, LIMITED PARTNERSHIP

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month